The global naltrexone and buprenorphine market size was estimated at USD 4.17 billion in 2024 and is projected to reach USD 9.80 billion by 2033, growing at a CAGR of 9.25% from 2025 to 2033. The market is expected to grow due to the increasing prevalence of substance use disorders and greater awareness of opioid use disorder treatments. Government initiatives are further increasing access to advanced addiction care solutions.
This product will be delivered within 2 business days.
WHO Updates Opioid Treatment Guidelines
In February 2025, The World Health Organization (WHO) updated its guidelines on opioid dependence treatment and overdose prevention to expand access to effective interventions. The revised guidelines emphasized the importance of using opioid agonist maintenance treatment (OAMT) with methadone or buprenorphine as the most effective therapy for opioid dependence. WHO also recommended making naloxone more widely available to prevent overdose-related deaths, especially in community settings. The new guidance called for reducing regulatory barriers and increasing investment in harm-reduction services. Additionally, the update urged healthcare providers to deliver evidence-based, person-centered, and non-discriminatory care. These recommendations were aimed at supporting countries in addressing rising opioid-related health challenges and enhancing public health outcomes globally.Global Naltrexone And Buprenorphine Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global naltrexone and buprenorphine market report based on product, route of administration, application, distribution channel, and region:Product Outlook (Revenue, USD Million, 2021 - 2033)
- Naltrexone
- Buprenorphine
- BELBUCA
- Sublocade
- Suboxone
- Zubsolv
- Others
Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
- Naltrexone
- Oral Administration
- Injectable Administration
- Implantable Administration
- Buprenorphine
- Oral Administration
- Injectable Administration
- Implantable Administration
Application Outlook (Revenue, USD Million, 2021 - 2033)
- Naltrexone
- Opioid use disorder (OUD)
- Alcohol use disorder (AUD
- Buprenorphine
- Opioid use disorder (OUD)
Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals Pharmacies
- Retail Pharmacies
- Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Route of Administration
1.2.3. Application
1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
1.2. Segment Definitions
1.2.1. Product
1.2.2. Route of Administration
1.2.3. Application
1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Naltrexone and Buprenorphine Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Naltrexone and Buprenorphine Market: Product Business Analysis
4.1. Product Market Share, 2024 & 2033
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Naltrexone
4.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
4.5. Buprenorphine
4.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
4.5.2. BELBUCA
4.5.2.1. BELBUCA Market, 2021 - 2033 (USD Million)
4.5.3. Sublocade
4.5.3.1. Sublocade Market, 2021 - 2033 (USD Million)
4.5.4. Suboxone
4.5.4.1. Suboxone Market, 2021 - 2033 (USD Million)
4.5.5. Zubsolv
4.5.5.1. Zubsolv Market, 2021 - 2033 (USD Million)
4.5.6. Others
4.5.6.1. Others Market, 2021 - 2033 (USD Million)
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2021 to 2033 (USD Million)
4.4. Naltrexone
4.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
4.5. Buprenorphine
4.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
4.5.2. BELBUCA
4.5.2.1. BELBUCA Market, 2021 - 2033 (USD Million)
4.5.3. Sublocade
4.5.3.1. Sublocade Market, 2021 - 2033 (USD Million)
4.5.4. Suboxone
4.5.4.1. Suboxone Market, 2021 - 2033 (USD Million)
4.5.5. Zubsolv
4.5.5.1. Zubsolv Market, 2021 - 2033 (USD Million)
4.5.6. Others
4.5.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 5. Naltrexone and Buprenorphine Market: Route of Administration Business Analysis
5.1. Route of Administration Market Share, 2024 & 2033
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
5.4. Naltrexone
5.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
5.4.2. Oral Administration
5.4.2.1. Oral Administration Market, 2021 - 2033 (USD Million)
5.4.3. Injectable Administration
5.4.3.1. Injectable Administration Market, 2021 - 2033 (USD Million)
5.4.4. Implantable Administration
5.4.4.1. Implantable Administration Market, 2021 - 2033 (USD Million)
5.5. Buprenorphine
5.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
5.5.2. Oral Administration
5.5.2.1. Oral Administration Market, 2021 - 2033 (USD Million)
5.5.3. Injectable Administration
5.5.3.1. Injectable Administration Market, 2021 - 2033 (USD Million)
5.5.4. Implantable Administration
5.5.4.1. Implantable Administration Market, 2021 - 2033 (USD Million)
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Route of administration, 2021 to 2033 (USD Million)
5.4. Naltrexone
5.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
5.4.2. Oral Administration
5.4.2.1. Oral Administration Market, 2021 - 2033 (USD Million)
5.4.3. Injectable Administration
5.4.3.1. Injectable Administration Market, 2021 - 2033 (USD Million)
5.4.4. Implantable Administration
5.4.4.1. Implantable Administration Market, 2021 - 2033 (USD Million)
5.5. Buprenorphine
5.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
5.5.2. Oral Administration
5.5.2.1. Oral Administration Market, 2021 - 2033 (USD Million)
5.5.3. Injectable Administration
5.5.3.1. Injectable Administration Market, 2021 - 2033 (USD Million)
5.5.4. Implantable Administration
5.5.4.1. Implantable Administration Market, 2021 - 2033 (USD Million)
Chapter 6. Naltrexone and Buprenorphine Market: Application Business Analysis
6.1. Application Market Share, 2024 & 2033
6.2. Application Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Naltrexone
6.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
6.4.2. Opioid use disorder (OUD)
6.4.2.1. Opioid use disorder (OUD) Market, 2021 - 2033 (USD Million)
6.4.3. Alcohol use disorder (AUD)
6.4.3.1. Alcohol use disorder (AUD) Market, 2021 - 2033 (USD Million)
6.5. Buprenorphine
6.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
6.5.2. Opioid use disorder (OUD)
6.5.2.1. Opioid use disorder (OUD) Market, 2021 - 2033 (USD Million)
6.2. Application Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
6.4. Naltrexone
6.4.1. Naltrexone Market, 2021 - 2033 (USD Million)
6.4.2. Opioid use disorder (OUD)
6.4.2.1. Opioid use disorder (OUD) Market, 2021 - 2033 (USD Million)
6.4.3. Alcohol use disorder (AUD)
6.4.3.1. Alcohol use disorder (AUD) Market, 2021 - 2033 (USD Million)
6.5. Buprenorphine
6.5.1. Buprenorphine Market, 2021 - 2033 (USD Million)
6.5.2. Opioid use disorder (OUD)
6.5.2.1. Opioid use disorder (OUD) Market, 2021 - 2033 (USD Million)
Chapter 7. Naltrexone and Buprenorphine Market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2024 & 2033
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
7.5. Retail Pharmacies
7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
7.6. Others
7.6.1. Others Market, 2021 - 2033 (USD Million)
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
7.5. Retail Pharmacies
7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
7.6. Others
7.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 8. Naltrexone and Buprenorphine Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2033
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
8.4. North America
8.4.1. North America Naltrexone and Buprenorphine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. End Use Disease Prevalence
8.4.2.3. Regulatory Framework
8.4.2.4. Reimbursement Framework
8.4.2.5. U.S. Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. End Use Disease Prevalence
8.4.3.3. Regulatory Framework
8.4.3.4. Reimbursement Framework
8.4.3.5. U.S. Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. End Use Disease Prevalence
8.4.4.3. Regulatory Framework
8.4.4.4. Reimbursement Framework
8.4.4.5. Mexico Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Europe
8.5.1. Europe Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. End Use Disease Prevalence
8.5.2.3. Regulatory Framework
8.5.2.4. Reimbursement Framework
8.5.2.5. Uk Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. End Use Disease Prevalence
8.5.3.3. Regulatory Framework
8.5.3.4. Reimbursement Framework
8.5.3.5. Germany Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. End Use Disease Prevalence
8.5.4.3. Regulatory Framework
8.5.4.4. Reimbursement Framework
8.5.4.5. France Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. End Use Disease Prevalence
8.5.5.3. Regulatory Framework
8.5.5.4. Reimbursement Framework
8.5.5.5. Italy Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. End Use Disease Prevalence
8.5.6.3. Regulatory Framework
8.5.6.4. Reimbursement Framework
8.5.6.5. Spain Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.7. Denmark
8.5.7.1. Key Country Dynamics
8.5.7.2. End Use Disease Prevalence
8.5.7.3. Regulatory Framework
8.5.7.4. Reimbursement Framework
8.5.7.5. Denmark Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.8. Sweden
8.5.8.1. Key Country Dynamics
8.5.8.2. End Use Disease Prevalence
8.5.8.3. Regulatory Framework
8.5.8.4. Reimbursement Framework
8.5.8.5. Sweden Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.9. Norway
8.5.9.1. Key Country Dynamics
8.5.9.2. End Use Disease Prevalence
8.5.9.3. Regulatory Framework
8.5.9.4. Reimbursement Framework
8.5.9.5. Norway Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. End Use Disease Prevalence
8.6.2.3. Regulatory Framework
8.6.2.4. Reimbursement Framework
8.6.2.5. Japan Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. End Use Disease Prevalence
8.6.3.3. Regulatory Framework
8.6.3.4. Reimbursement Framework
8.6.3.5. China Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. End Use Disease Prevalence
8.6.4.3. Regulatory Framework
8.6.4.4. Reimbursement Framework
8.6.4.5. India Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.5. Australia
8.6.5.1. Key Country Dynamics
8.6.5.2. End Use Disease Prevalence
8.6.5.3. Regulatory Framework
8.6.5.4. Reimbursement Framework
8.6.5.5. Australia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.6. South Korea
8.6.6.1. Key Country Dynamics
8.6.6.2. End Use Disease Prevalence
8.6.6.3. Regulatory Framework
8.6.6.4. Reimbursement Framework
8.6.6.5. South Korea Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. End Use Disease Prevalence
8.6.7.3. Regulatory Framework
8.6.7.4. Reimbursement Framework
8.6.7.5. Thailand Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Latin America
8.7.1. Latin America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. End Use Disease Prevalence
8.7.2.3. Regulatory Framework
8.7.2.4. Reimbursement Framework
8.7.2.5. Japan Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. End Use Disease Prevalence
8.7.3.3. Regulatory Framework
8.7.3.4. Reimbursement Framework
8.7.3.5. China Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Middle East and Africa
8.8.1. Middle East and Africa Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. End Use Disease Prevalence
8.8.2.3. Regulatory Framework
8.8.2.4. Reimbursement Framework
8.8.2.5. South Africa Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. End Use Disease Prevalence
8.8.3.3. Regulatory Framework
8.8.3.4. Reimbursement Framework
8.8.3.5. Saudi Arabia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. End Use Disease Prevalence
8.8.4.3. Regulatory Framework
8.8.4.4. Reimbursement Framework
8.8.4.5. UAE Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. End Use Disease Prevalence
8.8.5.3. Regulatory Framework
8.8.5.4. Reimbursement Framework
8.8.5.5. Kuwait Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
8.4. North America
8.4.1. North America Naltrexone and Buprenorphine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. End Use Disease Prevalence
8.4.2.3. Regulatory Framework
8.4.2.4. Reimbursement Framework
8.4.2.5. U.S. Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. End Use Disease Prevalence
8.4.3.3. Regulatory Framework
8.4.3.4. Reimbursement Framework
8.4.3.5. U.S. Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. End Use Disease Prevalence
8.4.4.3. Regulatory Framework
8.4.4.4. Reimbursement Framework
8.4.4.5. Mexico Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5. Europe
8.5.1. Europe Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. End Use Disease Prevalence
8.5.2.3. Regulatory Framework
8.5.2.4. Reimbursement Framework
8.5.2.5. Uk Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. End Use Disease Prevalence
8.5.3.3. Regulatory Framework
8.5.3.4. Reimbursement Framework
8.5.3.5. Germany Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. End Use Disease Prevalence
8.5.4.3. Regulatory Framework
8.5.4.4. Reimbursement Framework
8.5.4.5. France Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. End Use Disease Prevalence
8.5.5.3. Regulatory Framework
8.5.5.4. Reimbursement Framework
8.5.5.5. Italy Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. End Use Disease Prevalence
8.5.6.3. Regulatory Framework
8.5.6.4. Reimbursement Framework
8.5.6.5. Spain Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.7. Denmark
8.5.7.1. Key Country Dynamics
8.5.7.2. End Use Disease Prevalence
8.5.7.3. Regulatory Framework
8.5.7.4. Reimbursement Framework
8.5.7.5. Denmark Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.8. Sweden
8.5.8.1. Key Country Dynamics
8.5.8.2. End Use Disease Prevalence
8.5.8.3. Regulatory Framework
8.5.8.4. Reimbursement Framework
8.5.8.5. Sweden Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.5.9. Norway
8.5.9.1. Key Country Dynamics
8.5.9.2. End Use Disease Prevalence
8.5.9.3. Regulatory Framework
8.5.9.4. Reimbursement Framework
8.5.9.5. Norway Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. End Use Disease Prevalence
8.6.2.3. Regulatory Framework
8.6.2.4. Reimbursement Framework
8.6.2.5. Japan Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. End Use Disease Prevalence
8.6.3.3. Regulatory Framework
8.6.3.4. Reimbursement Framework
8.6.3.5. China Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. End Use Disease Prevalence
8.6.4.3. Regulatory Framework
8.6.4.4. Reimbursement Framework
8.6.4.5. India Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.5. Australia
8.6.5.1. Key Country Dynamics
8.6.5.2. End Use Disease Prevalence
8.6.5.3. Regulatory Framework
8.6.5.4. Reimbursement Framework
8.6.5.5. Australia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.6. South Korea
8.6.6.1. Key Country Dynamics
8.6.6.2. End Use Disease Prevalence
8.6.6.3. Regulatory Framework
8.6.6.4. Reimbursement Framework
8.6.6.5. South Korea Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. End Use Disease Prevalence
8.6.7.3. Regulatory Framework
8.6.7.4. Reimbursement Framework
8.6.7.5. Thailand Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7. Latin America
8.7.1. Latin America Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. End Use Disease Prevalence
8.7.2.3. Regulatory Framework
8.7.2.4. Reimbursement Framework
8.7.2.5. Japan Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. End Use Disease Prevalence
8.7.3.3. Regulatory Framework
8.7.3.4. Reimbursement Framework
8.7.3.5. China Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8. Middle East and Africa
8.8.1. Middle East and Africa Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. End Use Disease Prevalence
8.8.2.3. Regulatory Framework
8.8.2.4. Reimbursement Framework
8.8.2.5. South Africa Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. End Use Disease Prevalence
8.8.3.3. Regulatory Framework
8.8.3.4. Reimbursement Framework
8.8.3.5. Saudi Arabia Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. End Use Disease Prevalence
8.8.4.3. Regulatory Framework
8.8.4.4. Reimbursement Framework
8.8.4.5. UAE Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. End Use Disease Prevalence
8.8.5.3. Regulatory Framework
8.8.5.4. Reimbursement Framework
8.8.5.5. Kuwait Naltrexone and Buprenorphine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Indivior PLC
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Collegium Pharmaceutical (BioDelivery Sciences International, Inc.)
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Alkermes, Inc.
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Orexo US, Inc. (a part of Orexo AB)
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Titan Pharmaceuticals, Inc.
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. Omeros Corporation
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Camurus
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Sun Pharmaceutical Industries Ltd
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Indivior PLC
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Collegium Pharmaceutical (BioDelivery Sciences International, Inc.)
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Alkermes, Inc.
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Orexo US, Inc. (a part of Orexo AB)
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Titan Pharmaceuticals, Inc.
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. Omeros Corporation
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Camurus
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Sun Pharmaceutical Industries Ltd
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Naltrexone and buprenorphine market, by region, 2021 - 2033 (USD Million)
Table 4 Global Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 5 Global Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 6 Global Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 7 Global Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 8 North America Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 9 North America Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 10 North America Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 11 North America Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 12 North America Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 13 U.S. Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 14 U.S. Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 15 U.S. Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 16 U.S. Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 17 Canada Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 18 Canada Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 19 Canada Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 20 Canada Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 21 Mexico Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 22 Mexico Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 23 Mexico Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 24 Mexico Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 25 Europe Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 26 Europe Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 27 Europe Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 28 Europe Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 29 Europe Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 30 UK Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 31 UK Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 32 UK Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 33 UK Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 34 Germany Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 35 Germany Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 36 Germany Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 37 Germany Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 38 France Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 39 France Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 40 France Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 41 France Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 42 Italy Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 43 Italy Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 44 Italy Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 45 Italy Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 46 Spain Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 47 Spain Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 48 Spain Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 49 Spain Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 50 Norway Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 51 Norway Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 52 Norway Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 53 Norway Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 54 Denmark Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 55 Denmark Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 56 Denmark Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 57 Denmark Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 58 Sweden Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 59 Sweden Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 60 Sweden Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 61 Sweden Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 62 Asia Pacific Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 63 Asia Pacific Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD
Table 64 Asia Pacific Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 65 Asia Pacific Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 66 Asia Pacific Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 67 Japan Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 68 Japan Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 69 Japan Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 70 Japan Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 71 China Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 72 China Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 73 China Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 74 China Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 75 India Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 76 India Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 77 India Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 78 India Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 79 Australia Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 80 Australia Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 81 Australia Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 82 Australia Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 83 South Korea Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 84 South Korea Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 85 South Korea Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 86 South Korea Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 87 Thailand Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 88 Thailand Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 89 Thailand Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 90 Thailand Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 91 Latin America Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 92 Latin America Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 93 Latin America Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 94 Latin America Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 95 Latin America Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 96 Brazil Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 97 Brazil Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 98 Brazil Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 99 Brazil Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 100 Argentina Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 101 Argentina Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 102 Argentina Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 103 Argentina Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 104 Middle East & Africa Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 105 Middle East & Africa Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 106 Middle East & Africa Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 107 Middle East & Africa Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 108 Middle East & Africa Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 109 South Africa Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 110 South Africa Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 111 South Africa Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 112 South Africa Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 113 Saudi Arabia Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 114 Saudi Arabia Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 115 Saudi Arabia Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 116 Saudi Arabia Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 117 UAE Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 118 UAE Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 119 UAE Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 120 UAE Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 121 Kuwait Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 122 Kuwait Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 123 Kuwait Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 124 Kuwait Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 2 List of abbreviations
Table 3 Global Naltrexone and buprenorphine market, by region, 2021 - 2033 (USD Million)
Table 4 Global Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 5 Global Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 6 Global Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 7 Global Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 8 North America Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 9 North America Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 10 North America Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 11 North America Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 12 North America Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 13 U.S. Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 14 U.S. Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 15 U.S. Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 16 U.S. Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 17 Canada Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 18 Canada Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 19 Canada Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 20 Canada Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 21 Mexico Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 22 Mexico Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 23 Mexico Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 24 Mexico Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 25 Europe Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 26 Europe Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 27 Europe Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 28 Europe Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 29 Europe Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 30 UK Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 31 UK Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 32 UK Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 33 UK Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 34 Germany Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 35 Germany Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 36 Germany Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 37 Germany Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 38 France Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 39 France Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 40 France Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 41 France Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 42 Italy Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 43 Italy Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 44 Italy Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 45 Italy Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 46 Spain Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 47 Spain Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 48 Spain Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 49 Spain Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 50 Norway Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 51 Norway Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 52 Norway Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 53 Norway Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 54 Denmark Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 55 Denmark Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 56 Denmark Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 57 Denmark Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 58 Sweden Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 59 Sweden Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 60 Sweden Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 61 Sweden Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 62 Asia Pacific Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 63 Asia Pacific Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD
Table 64 Asia Pacific Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 65 Asia Pacific Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 66 Asia Pacific Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 67 Japan Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 68 Japan Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 69 Japan Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 70 Japan Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 71 China Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 72 China Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 73 China Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 74 China Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 75 India Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 76 India Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 77 India Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 78 India Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 79 Australia Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 80 Australia Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 81 Australia Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 82 Australia Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 83 South Korea Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 84 South Korea Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 85 South Korea Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 86 South Korea Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 87 Thailand Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 88 Thailand Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 89 Thailand Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 90 Thailand Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 91 Latin America Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 92 Latin America Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 93 Latin America Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 94 Latin America Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 95 Latin America Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 96 Brazil Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 97 Brazil Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 98 Brazil Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 99 Brazil Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 100 Argentina Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 101 Argentina Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 102 Argentina Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 103 Argentina Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 104 Middle East & Africa Naltrexone and buprenorphine market, by country, 2021 - 2033 (USD Million)
Table 105 Middle East & Africa Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 106 Middle East & Africa Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 107 Middle East & Africa Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 108 Middle East & Africa Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 109 South Africa Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 110 South Africa Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 111 South Africa Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 112 South Africa Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 113 Saudi Arabia Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 114 Saudi Arabia Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 115 Saudi Arabia Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 116 Saudi Arabia Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 117 UAE Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 118 UAE Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 119 UAE Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 120 UAE Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
Table 121 Kuwait Naltrexone and buprenorphine market, by product, 2021 - 2033 (USD Million)
Table 122 Kuwait Naltrexone and buprenorphine market, by route of administration, 2021 - 2033 (USD Million)
Table 123 Kuwait Naltrexone and buprenorphine market, by application, 2021 - 2033 (USD Million)
Table 124 Kuwait Naltrexone and buprenorphine market, by distribution channel, 2021 - 2033 (USD Million)
List of Figures
Fig. 1 Naltrexone and buprenorphine market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and application outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Naltrexone and buprenorphine market dynamics
Fig. 12 Naltrexone and buprenorphine market: Porter’s five forces analysis
Fig. 13 Naltrexone and buprenorphine market: PESTLE analysis
Fig. 14 Product market, 2021 - 2033 (USD Million)
Fig. 15 Naltrexone market, 2021 - 2033 (USD Million)
Fig. 16 Buprenorphine market, 2021 - 2033 (USD Million)
Fig. 17 BELBUCA market, 2021 - 2033 (USD Million)
Fig. 18 Sublocade market, 2021 - 2033 (USD Million)
Fig. 19 Suboxone market, 2021 - 2033 (USD Million)
Fig. 20 Zubsolv market, 2021 - 2033 (USD Million)
Fig. 21 Others market, 2021 - 2033 (USD Million)
Fig. 22 Route of Administration market, 2021 - 2033 (USD Million)
Fig. 23 Naltrexone market, 2021 - 2033 (USD Million)
Fig. 24 Oral Administration market, 2021 - 2033 (USD Million)
Fig. 25 Injectable Administration market, 2021 - 2033 (USD Million)
Fig. 26 Implantable Administration market, 2021 - 2033 (USD Million)
Fig. 27 Buprenorphine market, 2021 - 2033 (USD Million)
Fig. 28 Oral Administration market, 2021 - 2033 (USD Million)
Fig. 29 Injectable Administration market, 2021 - 2033 (USD Million)
Fig. 30 Implantable Administration market, 2021 - 2033 (USD Million)
Fig. 31 Application market, 2021 - 2033 (USD Million)
Fig. 32 Naltrexone market, 2021 - 2033 (USD Million)
Fig. 33 Opioid use disorder (OUD) market, 2021 - 2033 (USD Million)
Fig. 34 Alcohol use disorder (AUD) market, 2021 - 2033 (USD Million)
Fig. 35 Buprenorphine market, 2021 - 2033 (USD Million)
Fig. 36 Opioid use disorder (OUD) market, 2021 - 2033 (USD Million)
Fig. 37 Distribution Channel market, 2021 - 2033 (USD Million)
Fig. 38 Hospital Pharmacies market, 2021 - 2033 (USD Million)
Fig. 39 Retail Pharmacies market, 2021 - 2033 (USD Million)
Fig. 40 Others market, 2021 - 2033 (USD Million)
Fig. 41 Naltrexone and buprenorphine market revenue, by region
Fig. 42 Regional marketplace: Key takeaways
Fig. 43 North America Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 44 U.S. country dynamics
Fig. 45 U.S. Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 46 Canada country dynamics
Fig. 47 Canada Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 48 Mexico country dynamics
Fig. 49 Mexico Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 50 Europe Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 51 UK country dynamics
Fig. 52 UK Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 53 Germany country dynamics
Fig. 54 Germany Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 55 France country dynamics
Fig. 56 France Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 57 Italy country dynamics
Fig. 58 Italy Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 59 Spain country dynamics
Fig. 60 Spain Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 61 Norway country dynamics
Fig. 62 Norway Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 63 Sweden country dynamics
Fig. 64 Sweden Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 65 Denmark country dynamics
Fig. 66 Denmark Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 67 Asia Pacific Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 68 Japan country dynamics
Fig. 69 Japan Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 70 China country dynamics
Fig. 71 China Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 72 India country dynamics
Fig. 73 India Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 74 Australia country dynamics
Fig. 75 Australia Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 76 South Korea country dynamics
Fig. 77 South Korea Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 78 Thailand country dynamics
Fig. 79 Thailand Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 80 Latin America Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 81 Brazil country dynamics
Fig. 82 Brazil Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 83 Argentina country dynamics
Fig. 84 Argentina Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 85 MEA Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 86 South Africa country dynamics
Fig. 87 South Africa Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 88 Saudi Arabia country dynamics
Fig. 89 Saudi Arabia Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 90 UAE country dynamics
Fig. 91 UAE Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 92 Kuwait country dynamics
Fig. 93 Kuwait Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 94 Company categorization
Fig. 95 Company market position analysis
Fig. 96 Strategic framework
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and application outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Naltrexone and buprenorphine market dynamics
Fig. 12 Naltrexone and buprenorphine market: Porter’s five forces analysis
Fig. 13 Naltrexone and buprenorphine market: PESTLE analysis
Fig. 14 Product market, 2021 - 2033 (USD Million)
Fig. 15 Naltrexone market, 2021 - 2033 (USD Million)
Fig. 16 Buprenorphine market, 2021 - 2033 (USD Million)
Fig. 17 BELBUCA market, 2021 - 2033 (USD Million)
Fig. 18 Sublocade market, 2021 - 2033 (USD Million)
Fig. 19 Suboxone market, 2021 - 2033 (USD Million)
Fig. 20 Zubsolv market, 2021 - 2033 (USD Million)
Fig. 21 Others market, 2021 - 2033 (USD Million)
Fig. 22 Route of Administration market, 2021 - 2033 (USD Million)
Fig. 23 Naltrexone market, 2021 - 2033 (USD Million)
Fig. 24 Oral Administration market, 2021 - 2033 (USD Million)
Fig. 25 Injectable Administration market, 2021 - 2033 (USD Million)
Fig. 26 Implantable Administration market, 2021 - 2033 (USD Million)
Fig. 27 Buprenorphine market, 2021 - 2033 (USD Million)
Fig. 28 Oral Administration market, 2021 - 2033 (USD Million)
Fig. 29 Injectable Administration market, 2021 - 2033 (USD Million)
Fig. 30 Implantable Administration market, 2021 - 2033 (USD Million)
Fig. 31 Application market, 2021 - 2033 (USD Million)
Fig. 32 Naltrexone market, 2021 - 2033 (USD Million)
Fig. 33 Opioid use disorder (OUD) market, 2021 - 2033 (USD Million)
Fig. 34 Alcohol use disorder (AUD) market, 2021 - 2033 (USD Million)
Fig. 35 Buprenorphine market, 2021 - 2033 (USD Million)
Fig. 36 Opioid use disorder (OUD) market, 2021 - 2033 (USD Million)
Fig. 37 Distribution Channel market, 2021 - 2033 (USD Million)
Fig. 38 Hospital Pharmacies market, 2021 - 2033 (USD Million)
Fig. 39 Retail Pharmacies market, 2021 - 2033 (USD Million)
Fig. 40 Others market, 2021 - 2033 (USD Million)
Fig. 41 Naltrexone and buprenorphine market revenue, by region
Fig. 42 Regional marketplace: Key takeaways
Fig. 43 North America Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 44 U.S. country dynamics
Fig. 45 U.S. Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 46 Canada country dynamics
Fig. 47 Canada Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 48 Mexico country dynamics
Fig. 49 Mexico Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 50 Europe Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 51 UK country dynamics
Fig. 52 UK Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 53 Germany country dynamics
Fig. 54 Germany Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 55 France country dynamics
Fig. 56 France Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 57 Italy country dynamics
Fig. 58 Italy Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 59 Spain country dynamics
Fig. 60 Spain Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 61 Norway country dynamics
Fig. 62 Norway Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 63 Sweden country dynamics
Fig. 64 Sweden Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 65 Denmark country dynamics
Fig. 66 Denmark Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 67 Asia Pacific Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 68 Japan country dynamics
Fig. 69 Japan Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 70 China country dynamics
Fig. 71 China Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 72 India country dynamics
Fig. 73 India Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 74 Australia country dynamics
Fig. 75 Australia Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 76 South Korea country dynamics
Fig. 77 South Korea Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 78 Thailand country dynamics
Fig. 79 Thailand Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 80 Latin America Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 81 Brazil country dynamics
Fig. 82 Brazil Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 83 Argentina country dynamics
Fig. 84 Argentina Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 85 MEA Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 86 South Africa country dynamics
Fig. 87 South Africa Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 88 Saudi Arabia country dynamics
Fig. 89 Saudi Arabia Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 90 UAE country dynamics
Fig. 91 UAE Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 92 Kuwait country dynamics
Fig. 93 Kuwait Naltrexone and buprenorphine market, 2021 - 2033 (USD Million)
Fig. 94 Company categorization
Fig. 95 Company market position analysis
Fig. 96 Strategic framework
Companies Mentioned
- Indivior PLC
- Collegium Pharmaceutical (BioDelivery Sciences International, Inc.)
- Alkermes, Inc.
- Orexo US, Inc. (a part of Orexo AB)
- Titan Pharmaceuticals, Inc.
- Omeros Corporations
- Camurus
- Sun Pharmaceutical Industries Ltd
